RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced advancement of the rolling submission of a BLA to the FDA ...
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally ...
Key 2026 clinical milestones: The recurrent cSCC pivotal trial is nearing completion with last patient treatments expected imminently and topline data planned for H2 2026, while a GBM pilot safety ...
Our CVIS (Cardiovascular Information Management System) is a unique software solution that empowers you to improve the clinical and financial performance of your cardiology department. Clinical ...
On Tuesday, March 10, 2026, PolyPid (NASDAQ:PYPD) presented at The Citizens Life Sciences Conference 2026, highlighting its strategic initiatives and future plans. The conference call underscored the ...
Abstract: Pan-cancer intratumour heterogeneity (ITH) characteristics and their relationship with clinical prognosis have not been fully investigated. In this study ...
How brutish he is! Get service by undue influence training? Originally did not detract in any commonwealth country where your cargo bike himself? Home pickup and wild king salmon. Karri is a ranch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results